Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Blog Article

Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors Silicone Funnel (NETs), which overexpressed somatostatin receptors.However, after progression there are a limited number of available treatments.We want to share a case report about a patient with a NET re-treated with 177Lu-DOTATATE and a literature review about salvage treatment with PRRT.We present a 26-year-old man who started with pelvic pain and after a biopsy of a retro-rectal mass observed in a magnetic resonance was diagnosed with an advanced neuroendocrine tumour.

After progression to lanreotide, everolimus and sunitinib, treatment with 177Lu-DOTATATE was initiated, achieving an excellent response with a progression free survival (PFS) of 38 months.At the time of progression, re-treatment with 177Lu-DOTATATE was decided, showing a Oximeters new partial response, which is currently stable after 15 months.The patient had not presented significant treatment-related toxicity.Although there are no randomized phase III trials or a consensus about the number or dose of cycles, there is evidence about the efficacy and low toxicity of salvage treatment with 177Lu-DOTATATE in NETs.

Median progression-free survival ranges from 6 to 22 months.Toxicity is mostly hematologic (anemia and neutropenia), 4-7% grade 3/4.